CN103566020A - Traditional Chinese medicinal composition for preventing and treating female climacteric syndrome - Google Patents
Traditional Chinese medicinal composition for preventing and treating female climacteric syndrome Download PDFInfo
- Publication number
- CN103566020A CN103566020A CN201310390063.8A CN201310390063A CN103566020A CN 103566020 A CN103566020 A CN 103566020A CN 201310390063 A CN201310390063 A CN 201310390063A CN 103566020 A CN103566020 A CN 103566020A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- medicine composition
- parts
- alcoholic solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a traditional Chinese medicinal composition for preventing and treating female climacteric syndrome and a preparation method of the traditional Chinese medicinal composition. Effective ingredients for preparing the traditional Chinese medicinal composition for preventing and treating female climacteric syndrome consist of the following raw materials in parts by weight: 2-8 parts of prepared rehmannia root, 1-2 parts of coptis chinensis, 3-9 parts of white paeony root, 7-11 parts of colla corii asini, 11-18 parts of scutellaria baicalensis, 2-6 parts of Tuckahoe and 1-3 parts of pseudo-ginseng. The traditional Chinese medicinal composition includes quick-release granules and slow-release granules; and a clinical trial proves that the traditional Chinese medicinal composition has an obvious clinical effect on female climacteric syndrome and is convenient to take once a day.
Description
Technical field
The present invention relates to Chinese medicine preparation, be specifically related to a kind of Chinese medicine formula and manufacture method with control female dimacteric syndrome disease.
Background technology
Climacteric syndrome refers to women at climacteric or thereafter, and because ovarian function fails gradually or loses, so that decrease in estrogen is caused take autonomic nervous dysfunction's dysbolismus as main a series of syndromes.Climacteric just refers to women's climacteric, is generally 45 years old to 55 years old, and average age of meuopause is 49 years old.If there is menopause, just belong to ovarian function decline, the thing followed is the hectic fever hyperhidrosis causing in various degree, anxiety-depression, the climacteric syndrome shapes such as susceptible to lose temper due to restlessness.Generally when Menopausal transitional period menoxenia, symptom started to occur, may persist to 2-3 after menopause, and only a few peoples just can alleviate or disappear to symptom after menopause 5-10.Climacteric is the stage that each women must experience, but everyone symptom weight showing is not etc., of long duration wouldn't one, light can be safe and sound, heavy can affect work and life, even can develop into climacteric syndrome.Short some months, long continues several years.Although climacteric syndrome shows as many symptoms, its essence is that women is in the process of a hormonal change must experiencing in life.China approximately has 1,200,000 women to die from the major disease that climacteric syndrome causes every year; In climacteric women, there is 30% people to suffer from hysteromyoma, ovarian cyst.Doubly, hypertensive sickness rate is between twenty and fifty 6 times to the 5-6 that the sickness rate of climacteric women trouble coronary heart disease is non-climacteric women.Especially in climacteric late period, the sickness rate of hypertension, coronary atherosclerosis and myocardial infarction rises rapidly.In Female Patients of Diabetes patient, 70% is to occur before and after climacteric.75% women with breast cancer patient is the women before and after climacteric, and the sickness rate that before and after climacteric, women suffers from breast cancer is higher by 68% than normal person.Treatment is divided into western medical treatment and Chinese traditional treatment, and it is the effective medicine for the treatment of climacteric syndrome that its integrative therapy is selected controversies in hormone replacement in the elderly estrogen.It can alleviate the cardiovascular symptom of menolipsis early stage, Hou phase, the symptoms such as hectic fever, flushing, anxiety, depression are had to obvious curative effect, alleviate spirit, nervous symptoms, eliminate senile vaginitis and urethritis, and have the effect of slow down senile osteoporosis and progression of atherosclerosis.But controversies in hormone replacement in the elderly has its indication and contraindication, also there is certain side effect.After climacteric, take estrogenic women and be easy to develop into gallbladder disease, also can increase clot and gather.These blood clottings can increase apoplexy, and heart attack and other diseases are dangerous.In addition, estrogenic also likely causes breast carcinoma, increases the risk of endometrium canceration.Chinese traditional treatment is of a great variety, also has in recent years a lot of effectively Chinese medicine preparation listing treatments by Chinese herbs, has the low feature of successful side effect.
< < Kuntai capsule discloses by Radix Rehmanniae Preparata the > > (Chinese geriatrics magazine the 23rd the 9th phase of volume of JIUYUE in 2004) that affects of hot flushes in rats ovary and Morphological examination of endometrial tissue, Rhizoma Coptidis, the Radix Paeoniae Alba, Colla Corii Asini, Radix Scutellariae, Poria forms conventional capsule preparation has certain Nutrition to uterus, it is evident in efficacy to treatment menopause syndrome that the clinical research > > (Chinese Journal of New Drugs the 14th the 12nd phase of volume in 2005) of < < Kuntai capsule treatment menopausal syndrome tells about this kind of capsule of knowing clearly, especially to menopause transition patient, may be improved the effect of ovarian function.Compared with decoction taking convenience, safe.Clinically can this kind of capsule of coupling and gonadotherapy, to reduce the consumption of two medicines.Although this capsule has as above benefit, need take every day three times, for needing the patient of long term administration to make troubles.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of Chinese medicine preparation, and this preparation has better effect, and only needs every day to take once, and action effect is lasting.
Prevent and treat a Chinese medicine composition for female dimacteric syndrome, the raw material that it is characterized in that preparing this medicine active ingredient used forms and is by weight: Radix Rehmanniae Preparata 2 ?8 parts, Rhizoma Coptidis 1 ?2 parts, the Radix Paeoniae Alba 3 ?9 parts, Colla Corii Asini 7 ?11 parts, Radix Scutellariae 11 ?18 parts, Poria 2 ?6 parts, Radix Notoginseng 1 ?3 parts.On this basis as a kind of optimized choice, the raw material of preparing this medicine active ingredient used forms and is preferably by weight: 1 part of Radix Rehmanniae Preparata 3-6 part, 1 part of Rhizoma Coptidis, Radix Paeoniae Alba 3-8 part, Colla Corii Asini 10-11 part, Radix Scutellariae 11-18 part, Poria 2-6 part, Radix Notoginseng.As a kind of optimization selection, the raw material composition of preparing this medicine active ingredient used is by weight: 5 parts, Radix Rehmanniae Preparata, 1 part of Rhizoma Coptidis, 5 parts of the Radix Paeoniae Albas, 10 parts, Colla Corii Asini, 11 parts of Radix Scutellariaes, 6 parts, Poria, 1 part of Radix Notoginseng.The present invention also provides a kind of method of preparing above-mentioned preparation: Radix Scutellariae, Poria, the Radix Paeoniae Alba, Radix Rehmanniae Preparata, Rhizoma Coptidis, Colla Corii Asini, Radix Notoginseng are shattered into coarse powder, with alcoholic solution, extract, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.15-1.5; Get 1/3rd extractum, add starch, make immediate-release granules, get 2/3rds extractum, add hypromellose, make slow-releasing granules; By above-mentioned two kinds of granule mix homogeneously, make capsule preparations.The concentration of extracting above-mentioned Chinese crude drug ethanol used is preferably 70-95%.As more optimal selection, extraction is preferably 95% by the concentration of alcoholic solution, and the extraction of effective ingredient is best like this.And the extraction time of alcoholic solution is preferably 1-5 time.As the extraction time of optimized selection alcoholic solution, being preferably is 2 times, so both can guarantee the extraction of effective ingredient, can reasonably use solvent again, and time and solvent avoid waste.Each extraction time of alcoholic solution is optimized for as 3-5 hour, and as optimal choice, each extraction time of alcoholic solution is preferably 3 hours.
Beneficial effect of the present invention:
1. the present invention has increased Radix Notoginseng in prescription, because Radix Notoginseng has the effect of invigorating blood circulation, with other drug synergism, has increased the curative effect of other drug, has received beyond thought effect.
2. the present invention has adopted heterogeneous drug delivery system, immediate-release granules and slow-releasing granules are in same capsule, brought into play the rapid-action effect of quick releasing formulation, brought into play again the feature of slow-releasing granules long action time, extended the action time of medicine, the number of times of taking that has reduced patient, facilitates patient's long term administration.
Accompanying drawing explanation:
Fig. 1: the comparison diagram of new drug group and matched group baicalin blood drug level;
Fig. 2: the comparison diagram of new drug group and matched group glycinemia concentration.
The specific embodiment
Radix Scutellariae, Poria, the Radix Paeoniae Alba, Radix Rehmanniae Preparata, Rhizoma Coptidis, Colla Corii Asini, Radix Notoginseng are shattered into coarse powder, with alcoholic solution, extract for several times, each amount of alcohol used is 150kg, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.15-1.5; Get 1/3rd extractum, add 2kg starch, make immediate-release granules; cross 80 mesh sieves; 50 ℃ of forced air dryings, get 2/3rds extractum, add hypromellose; make slow-releasing granules; cross 80 mesh sieves, 50 ℃ of forced air dryings, by above-mentioned two kinds of granule mix homogeneously; encapsulating capsule, makes 100000 capsule preparations.
Embodiment 1
Radix Scutellariae 11kg, Poria 6kg, Radix Paeoniae Alba 8kg, Radix Rehmanniae Preparata 3kg, Rhizoma Coptidis 1kg, Colla Corii Asini 11kg, Radix Notoginseng 3kg are shattered into coarse powder, with 95% alcoholic solution, extract 2 times, each extraction time is 3 hours, each amount of alcohol used is 150kg, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.2; Get 1/3rd extractum, add 2kg starch, make immediate-release granules; cross 80 mesh sieves; 50 ℃ of forced air dryings, get 2/3rds extractum, add hypromellose 3kg; make slow-releasing granules; cross 80 mesh sieves, 50 ℃ of forced air dryings, by above-mentioned two kinds of granule mix homogeneously; encapsulating capsule, makes 100000 capsule preparations.
Use double blinding, the method research that random, contrast outpatient observes, 30 experimenters are divided into two groups, new drug group: take the above-mentioned medicament capsule making every day, once a day, matched group is taken the medicament capsule that contains Radix Scutellariae, Poria, the Radix Paeoniae Alba, Radix Rehmanniae Preparata, Rhizoma Coptidis, Colla Corii Asini composition having gone on the market, every day three times, eight hours once, forbids taking other related preparations during treating.
The whole observation period is 2 months, for screening patient, monthly sees and treat patients for totally four times for twice afterwards for the first time.Each 5 symptoms of patient of giving are carried out classification marking (vexed peaceful, insomnia, dizziness and tinnitus, easily tired, night sweat), and each symptom marking standard is that 1-3 divides:
3 minutes, severe patient in symptom.Its order of severity is impatient at for patient, can not adhere to normal operation, has influence on daily life, must go to hospital to seek medical advice.
2 minutes, symptom was moderate.Have influence on daily life, though or have heavier degree to stand, adhere to general routine work.
1 minute, symptom was lighter.Symptom is generally low weight, can carry out general routine work.
0 minute, there is no symptom
Above 5 cardinal symptoms, severe person's total points is 15 minutes, moderate is 10 minutes, is slightly below 3 minutes.
Tested inclusive criteria: all participation observers are married healthy women, and meet condition:
1. have typical climacteric syndrome, comprehensive grading is more than 3 minutes.
2. decrease in estrogen in blood, and short ovum stimulin and flitropin level increase.
In 3.3 months, do not take hormone.
4. without medical histories such as breast carcinoma, uterus carcinoma, vaginal hemorrhage, cardiovascular diseases, hepatopathy, allergy.
Before and after taking medicine, the contrast of giving a mark.Patient's symptom score is averaged
Conclusion: as can be seen from the above table, before and after treatment, no matter be matched group or new drug group,
All there is obvious curative effect, and new drug group is compared effect with matched group more obvious, and only need take one time medicine every day.
Embodiment 2
Radix Scutellariae 11kg, Poria 6kg, Radix Paeoniae Alba 8kg, Radix Rehmanniae Preparata 8kg, Rhizoma Coptidis 2kg, Colla Corii Asini 7kg, Radix Notoginseng 1kg are shattered into coarse powder, with 75% alcoholic solution, extract 2 times, each extraction time is 5 hours, each amount of alcohol used is 150kg, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.2; Get 1/3rd extractum, add 2kg starch, make immediate-release granules; cross 80 mesh sieves; 50 ℃ of forced air dryings, get 2/3rds extractum, add hypromellose 3kg; make slow-releasing granules; cross 80 mesh sieves, 50 ℃ of forced air dryings, by above-mentioned two kinds of granule mix homogeneously; encapsulating capsule, makes 100000 capsule preparations.
By the method identical with embodiment 1, the medicine of embodiment 2 is carried out to clinical observation, result is as follows
Conclusion: as can be seen from the above table, before and after treatment, no matter be matched group or new drug group, all there is obvious curative effect, and new drug group compared effect with matched group more obvious, and only need take one time medicine every day.
Embodiment 3
Radix Scutellariae 11kg, Poria 6kg, Radix Paeoniae Alba 8kg, Radix Rehmanniae Preparata 8kg, Rhizoma Coptidis 2kg, Colla Corii Asini 7kg, Radix Notoginseng 1kg are shattered into coarse powder, with 75% alcoholic solution, extract 2 times, each extraction time is 5 hours, each amount of alcohol used is 150kg, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.15; Get 1/3rd extractum, add 2kg starch, make immediate-release granules; cross 80 mesh sieves; 50 ℃ of forced air dryings, get 2/3rds extractum, add hypromellose 3kg; make slow-releasing granules; cross 80 mesh sieves, 50 ℃ of forced air dryings, by above-mentioned two kinds of granule mix homogeneously; encapsulating capsule, makes 100000 capsule preparations.
By the method identical with embodiment 1, the medicine of embodiment 3 is carried out to clinical observation, result is as follows:
Conclusion: as can be seen from the above table, before and after treatment, no matter be matched group or new drug group, all there is obvious curative effect, and new drug group compared effect with matched group more obvious, and only need take one time medicine every day.
Embodiment 4
Radix Scutellariae 18kg, Poria 6kg, Radix Paeoniae Alba 9kg, Radix Rehmanniae Preparata 3kg, Rhizoma Coptidis 2kg, Colla Corii Asini 10kg, Radix Notoginseng 1kg are shattered into coarse powder, with 85% alcoholic solution, extract 2 times, each extraction time is 5 hours, each amount of alcohol used is 150kg, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.5; Get half extractum, add 2kg starch, make immediate-release granules; cross 80 mesh sieves; 50 ℃ of forced air dryings, get 2/3rds extractum, add hypromellose 3kg; make slow-releasing granules; cross 80 mesh sieves, 50 ℃ of forced air dryings, by above-mentioned two kinds of granule mix homogeneously; encapsulating capsule, makes 100000 capsule preparations.By the method identical with embodiment 1, the medicine of embodiment 4 is carried out to clinical observation, result is as follows:
Conclusion: as can be seen from the above table, before and after treatment, no matter be matched group or new drug group, all there is obvious curative effect, and new drug group compared effect with matched group more obvious, and only need take one time medicine every day.
Radix Scutellariae 11kg, Poria 2kg, Radix Paeoniae Alba 3kg, Radix Rehmanniae Preparata 6kg, Rhizoma Coptidis 2kg, Colla Corii Asini 11kg, Radix Notoginseng 1kg are shattered into coarse powder, with 70% alcoholic solution, extract 5 times, each extraction time is 5 hours, each amount of alcohol used is 150kg, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.5; Get 1/3rd extractum, add 2kg starch, make immediate-release granules; cross 80 mesh sieves; 50 ℃ of forced air dryings, get 2/3rds extractum, add hypromellose 3kg; make slow-releasing granules; cross 80 mesh sieves, 50 ℃ of forced air dryings, by above-mentioned two kinds of granule mix homogeneously; encapsulating capsule, makes 100000 capsule preparations.
By the method identical with embodiment 1, the medicine of embodiment 5 is carried out to clinical observation, result is as follows:
Conclusion: as can be seen from the above table, before and after treatment, no matter be matched group or new drug group, all there is obvious curative effect, and new drug group compared effect with matched group more obvious, and only need take one time medicine every day.
Embodiment 6
Radix Scutellariae 11kg, Poria 6kg, Radix Paeoniae Alba 5kg, Radix Rehmanniae Preparata 5kg, Rhizoma Coptidis 1kg, Colla Corii Asini 10kg, Radix Notoginseng 1kg are shattered into coarse powder, with 95% alcoholic solution, extract 2 times, each extraction time is 3 hours, each amount of alcohol used is 150kg, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.5; Get 1/3rd extractum, add 2kg starch, make immediate-release granules; cross 80 mesh sieves; 50 ℃ of forced air dryings, get 2/3rds extractum, add hypromellose 3kg; make slow-releasing granules; cross 80 mesh sieves, 50 ℃ of forced air dryings, by above-mentioned two kinds of granule mix homogeneously; encapsulating capsule, makes 100000 capsule preparations.
By the method identical with embodiment 1, the medicine of embodiment 5 is carried out to clinical observation, result is as follows:
Conclusion: as can be seen from the above table, before and after treatment, no matter be matched group or new drug group, all there is obvious curative effect, and new drug group compared effect with matched group more obvious, and only need take one time medicine every day.
Carry out pharmacokinetics experiment simultaneously
Take baicalin, glycine is control test, and above-mentioned preparation compares for dynamic experiment at blood samples of patients Chinese medicine, and after administration, every two hours blood drawing once, detects.
Liquid-phase condition:
Take octadecylsilane chemically bonded silica as filler; Take Yi Jing ?0.1mol/L sodium acetate solution (7:93) (take 30g sodium acetate as mobile phase A; adding water 3400ml dissolves; with vinegar acid for adjusting pH value to 6.5; then add water to 3700ml; add acetonitrile 280ml, shake up, obtain); take Yi Jing ?water (4:1) be Mobile phase B, according to the form below carries out gradient elution; Detection wavelength is 254nm; Column temperature is 43 ℃.Number of theoretical plate by L ?hydroxyproline peak calculate and should be not less than 4000.
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0-11.0 | 93.0 | 7 |
| 11.0-13.9 | 88.7 | 11.3 |
| 13.9-14.0 | 85.12 | 14.88 |
| 14.0-29.0 | 66.15 | 34.85 |
| 29.0-30.0 | 0 | 100 |
Glycine reference substance 25mg is got in the preparation of reference substance solution, puts in 50mL volumetric flask, with 0.1mol/L hydrochloric acid solution, is diluted to scale, obtains the baicalin reference substance storing solution of 0.5mg/mL.Accurate absorption glycine reference substance storing solution 0.1,0.2,0.5,1.0,2.0,4,8mL put respectively in 100mL volumetric flask respectively, use redistilled water standardize solution, are made into the serial glycine reference substance standard solution of 0.5,1,2.5,5,10,20,40 μ g/mL.
Precision takes baicalin reference substance 25mg, puts in 50mL volumetric flask, with dissolve with methanol and be diluted to scale, obtains the baicalin reference substance storing solution of 0.5mg/mL.Accurate absorption baicalin reference substance storing solution 0.1,0.2,0.5,1.0,2.0,4,8ml put respectively in 100mL volumetric flask respectively, use redistilled water standardize solution, are made into the serial baicalin reference substance standard solution of 0.5,1,2.5,5,10,20,40 μ g/mL.
The plasma sample of preparing of need testing solution is processed to get and is contained in a certain amount of blood plasma 0.4mL to 5mL centrifuge tube, add redistilled water 0.4mL, internal standard substance solution (0.45mg/L benzoic acid methanol solution) 0.4mL, acetonitrile 0.8mL, whirlpool mixing 30s, sonic oscillation 5min, centrifugal 10min on the high speed centrifuge of 3000r/min, get supernatant and filter through the organic filter membrane of 0.45 μ m micropore, get subsequent filtrate 10 μ L sample introductions, record chromatogram.
Each 10 μ L sample introductions of baicalin reference substance solution are got in detection, record chromatogram, drawing standard curve, abscissa is peak area, vertical coordinate is absworption peak area, obtain baicalin curvilinear equation formula, in like manner, get each 10 μ L sample introductions of glycine reference substance solution, record chromatogram, drawing standard curve, abscissa is peak area, and vertical coordinate is absworption peak area, obtains glycine curvilinear equation formula, according to the detection absworption peak of need testing solution, bring formula into and obtain need testing solution concentration, by calculating baicalin in blood plasma, glycine concentration.Correlated results is shown in Fig. 1, Fig. 2.Conclusion: the baicalin of new drug group and the blood drug level of glycine still keep certain numerical value after administration in 24 hours, avoided the big rise and big fall of matched group, and the slow releasing function of medicine is fully reflected.So the patient of new drug group only needs to take capsule once every day, take medicine conveniently.
Embodiment 7
Radix Scutellariae 11kg, Poria 6kg, Radix Paeoniae Alba 5kg, Radix Rehmanniae Preparata 2kg, Rhizoma Coptidis 2kg, Colla Corii Asini 10kg, Radix Notoginseng 1kg are shattered into coarse powder, with 90% alcoholic solution, extract 2 times, each extraction time is 3 hours, each amount of alcohol used is 150kg, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.15; Get 1/3rd extractum, add 2kg starch, make immediate-release granules; cross 80 mesh sieves; 50 ℃ of forced air dryings, get 2/3rds extractum, add hypromellose 3kg; make slow-releasing granules; cross 80 mesh sieves, 50 ℃ of forced air dryings, by above-mentioned two kinds of granule mix homogeneously; encapsulating capsule, makes 100000 capsule preparations.
By the method identical with embodiment 1, the medicine of embodiment 5 is carried out to clinical observation, result is as follows:
Conclusion: as can be seen from the above table, before and after treatment, no matter be matched group or new drug group, all there is obvious curative effect, and new drug group compared effect with matched group more obvious, and only need take one time medicine every day.
The above is the preferred embodiments of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of principle of the present invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (10)
1. a Chinese medicine composition of preventing and treating female dimacteric syndrome, it is characterized in that, the raw material composition of preparing this Chinese medicine composition active ingredient used is by weight: Radix Rehmanniae Preparata 2-8 part, Rhizoma Coptidis 1-2 part, Radix Paeoniae Alba 3-9 part, Colla Corii Asini 7-11 part, Radix Scutellariae 11-18 part, Poria 2-6 part, Radix Notoginseng 1-3 part.
2. Chinese medicine composition as claimed in claim 1, it is characterized in that, the raw material of preparing this Chinese medicine composition active ingredient used forms and to be by weight: 1 part of Radix Rehmanniae Preparata 3-6 part, 1 part of Rhizoma Coptidis, Radix Paeoniae Alba 3-8 part, Colla Corii Asini 10-11 part, Radix Scutellariae 11-18 part, Poria 2-6 part, Radix Notoginseng.
3. Chinese medicine composition as claimed in claim 2, is characterized in that, the raw material composition of preparing this Chinese medicine composition active ingredient used is by weight: 5 parts, Radix Rehmanniae Preparata, 1 part of Rhizoma Coptidis, 5 parts of the Radix Paeoniae Albas, 10 parts, Colla Corii Asini, 11 parts of Radix Scutellariaes, 6 parts, Poria, 1 part of Radix Notoginseng.
4. a method of preparing claim 1-3 any one Chinese medicine composition, comprise the steps: Radix Scutellariae, Poria, the Radix Paeoniae Alba, Radix Rehmanniae Preparata, Rhizoma Coptidis, Colla Corii Asini, Radix Notoginseng to shatter into coarse powder, with alcoholic solution, extract, by extracting liquid filtering, concentrated, the extractum that while making 40-60 ℃, relative density is 1.15-1.5; Get 1/3rd extractum, add starch, make immediate-release granules, get 2/3rds extractum, add hypromellose, make slow-releasing granules; By above-mentioned two kinds of granule mix homogeneously, make capsule preparations.
5. the preparation method of Chinese medicine composition as claimed in claim 4, is characterized in that extraction is 70-95% by the concentration of alcoholic solution.
6. the preparation method of Chinese medicine composition as claimed in claim 4, is characterized in that extraction is 95% by the concentration of alcoholic solution.
7. the preparation method of Chinese medicine composition as claimed in claim 4, the extraction time that it is characterized in that alcoholic solution is 1-5 time.
8. the preparation method of Chinese medicine composition as claimed in claim 7, the extraction time that it is characterized in that alcoholic solution is 2 times.
9. the preparation method of Chinese medicine composition as claimed in claim 4, the each extraction time that it is characterized in that alcoholic solution is 3-5 hour.
10. the preparation method of Chinese medicine composition as claimed in claim 4, the each extraction time that it is characterized in that alcoholic solution is 3 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310390063.8A CN103566020B (en) | 2013-08-30 | 2013-08-30 | A kind of Chinese medicine composition preventing and treating female dimacteric syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310390063.8A CN103566020B (en) | 2013-08-30 | 2013-08-30 | A kind of Chinese medicine composition preventing and treating female dimacteric syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103566020A true CN103566020A (en) | 2014-02-12 |
| CN103566020B CN103566020B (en) | 2015-12-09 |
Family
ID=50039301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310390063.8A Active CN103566020B (en) | 2013-08-30 | 2013-08-30 | A kind of Chinese medicine composition preventing and treating female dimacteric syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103566020B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679599A (en) * | 2004-04-05 | 2005-10-12 | 中国医学科学院药用植物研究所 | Double-layer delayed-releasing tablet of seudo-ginseng general saponin and production thereof |
| CN1733135A (en) * | 2005-08-19 | 2006-02-15 | 郭凌云 | Oral liquid for curing women's climacteric melancholia and process for preparing the same |
| CN1742870A (en) * | 2005-09-21 | 2006-03-08 | 黄如平 | Kuntai tablet preparation and preparation thereof |
| CN1850206A (en) * | 2006-02-21 | 2006-10-25 | 彭滢 | Medicine for treating women's climateric syndrome and preparing method |
| CN1865232A (en) * | 2006-06-22 | 2006-11-22 | 上海交通大学 | Method for extracting notoginseng essence from notoginseng |
| KR20060119047A (en) * | 2005-05-18 | 2006-11-24 | 장성팔 | Manufacturing method of herb medicine for a skin disease |
-
2013
- 2013-08-30 CN CN201310390063.8A patent/CN103566020B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679599A (en) * | 2004-04-05 | 2005-10-12 | 中国医学科学院药用植物研究所 | Double-layer delayed-releasing tablet of seudo-ginseng general saponin and production thereof |
| KR20060119047A (en) * | 2005-05-18 | 2006-11-24 | 장성팔 | Manufacturing method of herb medicine for a skin disease |
| CN1733135A (en) * | 2005-08-19 | 2006-02-15 | 郭凌云 | Oral liquid for curing women's climacteric melancholia and process for preparing the same |
| CN1742870A (en) * | 2005-09-21 | 2006-03-08 | 黄如平 | Kuntai tablet preparation and preparation thereof |
| CN1850206A (en) * | 2006-02-21 | 2006-10-25 | 彭滢 | Medicine for treating women's climateric syndrome and preparing method |
| CN1865232A (en) * | 2006-06-22 | 2006-11-22 | 上海交通大学 | Method for extracting notoginseng essence from notoginseng |
Non-Patent Citations (4)
| Title |
|---|
| 刘志刚等: "正交试验法优选黄芩总黄酮苷元酶解后提取工艺", 《中药新药与临床药理》 * |
| 张鹏霞等: "熟地提取液对衰老模型小鼠脑组织NOS、NO、SOD和L PO的影响", 《中国老年学杂志》 * |
| 徐晓燕等: "不同极性白芍提取物的抗氧化活性研究", 《食品与药品》 * |
| 范昌: "《三七药膳精粹》", 31 October 2004, 云南科技出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103566020B (en) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101780160B (en) | Traditional Chinese medicine preparation for treating gynecological disease and preparation method thereof | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| WO2010034134A1 (en) | Preparation method of concentrated pill of chinese medicine | |
| CN101569642A (en) | Medicament composition for accelerating sleeping as well as preparation method and application thereof | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN102908410A (en) | Chinese rhubarb extract for treating osteoporosis and climacteric syndrome | |
| CN102688361A (en) | Traditional Chinese medicinal composition for treating dysmenorrhoea and preparation thereof | |
| CN101732585A (en) | Medicinal composition for treating migraine, preparation method and application thereof | |
| CN101721624A (en) | Traditional Chinese medicine composition for treating menopausal syndrome and prepration method thereof | |
| CN103566020B (en) | A kind of Chinese medicine composition preventing and treating female dimacteric syndrome | |
| CN106466396B (en) | Gynaecologic menstruation regulating sustained-release dropping pill and preparation method thereof | |
| CN101352492A (en) | Medicament composition for treating cardio-cerebrovascular disease and regulating blood fat | |
| CN101249145B (en) | Nerves- soothing Chinese medicinal composition and its applications for preparing climacteric syndrome medicament | |
| CN100506219C (en) | Notoginseng hemostatic and its preparing method | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN103933152A (en) | Pharmaceutical composition for treating metrorrhagia and metrostaxis, pharmaceutical preparation and application and preparation method of pharmaceutical preparation | |
| CN113855754B (en) | Traditional Chinese medicine composition for removing blood stasis and stopping bleeding as well as preparation method and application thereof | |
| CN102552724A (en) | Chinese medicine composite for curing hypertension | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof | |
| CN108743676B (en) | Application method of white peony root in preparation of medicine for treating hypertension | |
| CN101766683A (en) | Salvia dispersible tablet and application thereof | |
| CN105395793A (en) | Application of traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris | |
| CN101940666B (en) | Traditional Chinese medicine composite for treating hyperlipoidemia and preparation method thereof | |
| CN104435149A (en) | Traditional Chinese medicine composition containing kadsura pepper stem for treating gout | |
| CN102552399B (en) | Traditional Chinese medicinal composition for clearing heat and calming liver and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |